Galactose Single Point (GSP), Residual Liver Function: Clinical Trials

2 trials for Galactose Single Point (GSP), Residual Liver Function, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 unknown. 1 Phase 1, 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 11Completed 1
Phase 21Completed 1
Phase 31Unknown 1

Follow Galactose Single Point (GSP), Residual Liver Function: new trials by email Literature Review of Galactose Single Point (GSP), Residual Liver Function trials Research Report on Galactose Single Point (GSP), Residual Liver Function

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Study for Development of Oral Galactose Single Point (OGSP) Solution (G.S.P. Oral Solution®)
G.S.P. Oral Solution 400 mg/ml - Galactose Single Point (GSP), Residual Liver Function
Phase 3UnknownRichever Enterprise Co., Ltd.2002013-09-092018-03-07
GSP as an Novel Indicator for Residual Liver Function in Patients With Fatty Liver
Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours. - Galactose Single Point (GSP), Residual Liver Function
Phase 1 / Phase 2CompletedNational Defense Medical Center, Taiwan2102007-07-052020-09-14

Narrower conditions

Pseudohypoparathyroidism (2)

Broader conditions

Bone Diseases (2)  ·  Bone Diseases, Metabolic (2)  ·  Calcium Metabolism Disorders (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Genetic Diseases, Inborn (2)  ·  Metabolic Diseases (2)  ·  Metabolism, Inborn Errors (2)  ·  Metal Metabolism, Inborn Errors (2)  ·  Musculoskeletal Diseases (2)  ·  Nutritional and Metabolic Diseases (2)

Sponsors

National Defense Medical Center, Taiwan (1)  ·  Richever Enterprise Co., Ltd. (1)